Dysentery Clinical Trial
Verified date | July 2012 |
Source | Hillel Yaffe Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | Israel: Ministry of Health |
Study type | Interventional |
The aim of this study is to accelerate the development of vaccine candidates against diarrheal diseases caused by Shigella and Enterotoxigenic Escherichia coli (ETEC). We plan to identify cases of laboratory-proven shigellosis and ETEC-associated diarrhea, to study humoral and cellular immune parameters following natural infections with Shigella and ETEC, and to compare the level of pre-existing local, humoral and cellular immune parameters in cases of shigellosis and ETEC-associated diarrhea and in matched controls.
Status | Not yet recruiting |
Enrollment | 330 |
Est. completion date | July 2016 |
Est. primary completion date | July 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | N/A to 65 Years |
Eligibility |
Inclusion Criteria: - Lab-confirmed Shigella or ETEC - Individuals or patients without diarrheal disease Exclusion Criteria: |
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Israel | Emek Medical Center | Afula | |
Israel | Hillel Yaffe Medical Center | Hadera | |
Israel | Lady Davis Carmel Medical Center | Haifa | |
Israel | Edith Wolfson Medical Center | Holon | |
Israel | Sansz Medical Center - Laniado Hospital | Netanya | |
Israel | Schneider Children's Medical Center | Petach Tikva | |
Israel | Leumit Health Care System | Petach Tikvah | Elad |
Lead Sponsor | Collaborator |
---|---|
Hillel Yaffe Medical Center | European Commission |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Identification of cases of shigellosis and ETEC-associated diarrhea | Stool of patients examined in laboratory and identified as infected with the pathogens | Four years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02280044 -
Efficacy of Rifaximin in Preventing Campylobacteriosis
|
Phase 2/Phase 3 | |
Completed |
NCT01080716 -
Safety and Efficacy Study of WRSS1, a Shigella Sonnei Vaccine Candidate
|
Phase 1/Phase 2 | |
Completed |
NCT00490932 -
New Hypo-Osmolar ORS (Recommended by WHO) for Routine Use in the Diarrhea Management– Surveillance Study for Adverse Effects
|
Phase 4 | |
Completed |
NCT01306383 -
Solar Disinfection (SODIS) of Drinking Water for Use in Developing Countries or in Emergency Situations
|
N/A | |
Completed |
NCT03561181 -
Safety Study of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months
|
Phase 1 | |
Completed |
NCT04865497 -
Immunogenicity and Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 3 Months to 5 Years Old
|
Phase 2 | |
Recruiting |
NCT05156528 -
Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years
|
Phase 3 | |
Completed |
NCT01672580 -
Social Network Interventions in Rural Honduras
|
N/A |